Resistance of uveal melanoma to the interstrand cross-linking agent mitomycin C is associated with reduced expression of CYP450R by Gravells, P et al.
Resistance of uveal melanoma to the interstrand cross-linking
agent mitomycin C is associated with reduced expression of
CYP450R
P Gravells
1, L Hoh
1,2, D Canovas
2, IG Rennie
2, K Sisley
2 and HE Bryant
1
1Department of Oncology, Faculty of Medicine Dentistry and Health Sciences, The Institute for Cancer Studies, University of Sheffield, Sheffield S10 2RX,
UK;
2Department of Oncology, Faculty of Medicine Dentistry and Health Sciences, Academic Unit of Ophthalmology and Orthoptics, University of
Sheffield, Royal Hallamshire Hospital, Sheffield, UK
BACKGROUND: Uveal melanoma (UM) is the most common primary intraocular tumour of adults, frequently metastasising to the liver.
Hepatic metastases are difficult to treat and are mainly unresponsive to chemotherapy. To investigate why UM are so chemo-
resistant we explored the effect of interstrand cross-linking agents mitomycin C (MMC) and cisplatin in comparison with hydroxyurea
(HU).
METHODS: Sensitivity to MMC, cisplatin and HU was tested in established UM cell lines using clonogenic assays. The response of UM to
MMC was confirmed in MTT assays using short-term cultures of primary UM. The expression of cytochrome P450 reductase
(CYP450R) was analysed by western blotting, and DNA cross-linking was assessed using COMET analysis supported by g-H2AX foci
formation.
RESULTS: Both established cell lines and primary cultures of UM were resistant to the cross-linking agent MMC (in each case Po0.001
in Student’s t-test compared with controls). In two established UM cell lines, DNA cross-link damage was not induced by MMC
(in both cases Po0.05 in Students’s t-test compared with damage induced in controls). In all, 6 out of 6 UMs tested displayed
reduced expression of the metabolising enzyme CYP450R and transient expression of CYP450R increased MMC sensitivity of UM.
CONCLUSION: We suggest that reduced expression of CYP450R is responsible for MMC resistance of UM, through a lack of
bioactivation, which can be reversed by complementing UM cell lines with CYP450R.
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Uveal melanoma (UM) arises from the melanocytes of the uveal
tract of the eye and can affect the iris, ciliary body and choroid. It
is a rare but aggressive cancer, that in countries with a large
Caucasian population, affects approximately 4–7 individuals per
million population annually and as such, it accounts for up to 80%
of all ocular tumours (Inskip et al, 2003; Singh et al, 2005). Current
treatments for the primary melanoma include enucleation and
local resection, various forms of radiation therapy and laser
hyperthermia (Harbour, 2003). The 5-year survival rate for UM is
approximately 60% (Virgili et al, 2008). Metastasis is common and
primarily presents in the liver as chemo-resistant secondary
tumours; consequently there is a poor prognosis of UM with
patient survival ranging from 2 to 12 months once hepatic
metastases are detected (Melichar et al, 2009). Difficulty in treating
hepatic metastasis arises because of the multi-focal nature of the
metastases and the ability to be, or to develop, multi-drug
resistance (MDR) (McNamara et al, 1996; Neale et al 2001). As a
result of the limited available treatment options for hepatic
metastases, there have been no improvements in overall survival
rates for patients with UM over the last 25 years. A greater
understanding of the effects that chemotherapeutic agents have in
UM may help towards developing new treatment strategies.
Many effective chemotherapeutic agents work as a consequence
of their ability to induce DNA damage. Mitomycin C (MMC) is a
natural antitumour antibiotic used for many years for cancer
chemotherapy. It kills cells by damaging DNA, primarily by
generating interstrand cross-links (ICLs) between cytosine and
guanine residues on opposite strands of the DNA duplex (Iyer and
Szybalski, 1963). In addition, MMC also forms intrastrand cross-
links between guanine residues on the same DNA strand (Bizanek
et al, 1992) and monofunctional alkylation of guanine residues
causing DNA adducts (Tomasz et al, 1986). However, these
interactions with DNA can only occur following the bioreductive
activation of MMC by various cellular reductases (Iyer and
Szybalski, 1963). Cisplatin also interacts with DNA, inducing
monoadducts, intrastrand cross-links and ICLs between guanine
residues; however, unlike MMC it does not require bioactivation.
The formation of cross-links is lethal to cells because replication is
inhibited. In contrast to the action of MMC and cisplatin,
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shydroxyurea (HU) does not act directly on DNA but is instead a
replication inhibitor thought to interact with catalase, and
targeting ribonucleotide reductase (Juul et al, 2010).
Despite its successful use in many different types of cancer,
including conjunctival melanoma (Chalasani et al, 2006), difficul-
ties in administration mean that MMC treatment has not been an
effective treatment for primary UM. In the treatment of metastatic
disease, MMC has been used in combination with other
chemotherapeutics but has produced only partial responses (Vogl
et al, 2007). However, evidence from one ex vivo study suggests
that approximately a third of primary UM may be sensitive to
MMC alone (Myatt et al, 1997). Cisplatin has been shown in
combination to be more effective in the management of UM, but
there are no independent studies of its effect singly (Bedikian,
2006; Dayani et al, 2009; Melichar et al, 2009). Furthermore, one
ex vivo study suggests that it may be even less effective than MMC
(Myatt et al, 1997). There are no reports of the use of HU in UM.
As MDR has severely hampered attempts to improve survival of
patients with UM, a better understanding of how these melanomas
respond to chemotherapeutic agents may assist in developing
improved treatment regimes. In this study, we investigate the
response of UM to MMC, cisplatin and HU using clonogenic and
MTT assays and explore the basis of this response.
MATERIALS AND METHODS
Plasmids
The pEF-P450R-IRES-P vector was a kind gift from Dr Kaye
Williams at the School of Pharmacy and Pharmaceutical Sciences,
University of Manchester, Manchester. For complementation
assays, 30mg of plasmid was transfected into 1 10
6 cells using
Lipofectamine 2000 reagent (Invitrogen, Paisley, UK) according to
the manufacturer’s instructions.
Cell lines and primary cultures
Established Sheffield Ocular Melanoma (SOM) cell lines, SOM
157d and SOM 196b were used alongside a panel of other human
control cell lines. All established cell lines were grown and treated
in DMEM with 10% fetal bovine serum, penicillin (100Uml
–1) and
streptomycin sulphate (100mgml
–1)a t3 71C under an atmosphere
containing 5% CO2. Short-term cultures were established from
primary UM as detailed previously (Elshaw et al, 2001) and were
maintained in RPMI-1640, supplemented with penicillin
(100Uml
–1), streptomycin (100mgml
–1), glucose (0.2%), epider-
mal growth factor (0.1%) and fetal calf serum (20%), at 371C under
an atmosphere containing 5% CO2. All short-term cultures were
used experimentally before passage 5. As there were insufficient
cells from these cultures to undertake all investigations, the use of
short-term cultures of primary UM was restricted to those
investigations were it was considered that they would provide
the most supportive and interesting information. Informed patient
consent was obtained from UM patients and protocols followed the
principles of the Declaration of Helsinki (SSREC94/247). The
clinical–pathological details of the patients are presented in
Table 1 and are representative for all clinical subgroups of UM.
Clonogenic survival assay
In order to characterise chemo-resistance in these tumours, we
performed a clonogenic survival assay with the common
chemotherapeutics MMC, cisplatin and HU. Established UM cell
lines SOM 157d and SOM 196b were compared with the cutaneous
melanoma cell line WM793, primary fibroblasts, the colon cancer
cell lines HCT116 and SW480 and the wild-type human fibroblast
cell line MRC5VA. A range of 500 to 5000 cells were plated in
triplicate onto 100mm dishes, 4h before treatment with increasing
doses of drugs as indicated. 10–14 days later, when colonies could
be observed, they were fixed and stained with methylene blue in
methanol (4gl
–1). Colonies consisting of 450 cells were sub-
sequently counted. Each colony was assumed to represent one
surviving cell from the starting population and the surviving
fraction for each dose was calculated.
MTT assays
Insufficient cells from short-term cultures of primary UM prohibited
their testing by clonogenic assay, so the MTT assay was employed.
MTT assays were performed using the Colorimetric Assay Prolifera-
tion Kit I (MTT) from Roche, Welwyn Garden City, UK, according to
the manufacturer’s instructions. Survival was calculated from the
relative absorbance in each cell line after 10 days growth in 50nM
M M Cc o m p a r e dw i t h1 0d a y sg r o w t hi nn o r m a lm e d i a .
c-H2AX foci formation
Cells were plated onto coverslips, allowed to settle for 4h and
grown for 1h in the presence or absence of 90nM MMC treatment.
Table 1 Clinicopathological details for patients with primary uveal melanoma, and correlation with genetic markers of poor prognosis
SOM Sex Cell type Tumour location
Copy number for chromosomes 3 and 8
respectively, as determined by FISH
a
SOM520 F Cilary body Spindle 2:2 Good prognosis
SOM524 F Ciliary body Mixed 2:3 Poor prognosis
SOM526 F Ciliary body Mixed 2:4 Poor prognosis
SOM530 M Choroid Spindle 2:2 Good prognosis
SOM533 F Choroid Spindle 2:3 Poor prognosis
SOM534 F Choroid Spindle 2:2 Good prognosis
SOM537 M Ciliary body+choroid Spindle 2:2 Good prognosis
SOM538 M Choroid Mixed 1:4 Poor prognosis
SOM544 M Choroid Spindle 2:2 Good prognosis
SOM545 F Choroid Epitheliod 1:4 Poor prognosis
SOM546 F Choroid Spindle 2:4 Poor prognosis
SOM547 F Choroid Spindle 2:2 Good prognosis
SOM550 — — — 1:2 Poor prognosis
Abbrevaitions: F¼female; FISH¼fluorescence in situ hybridization; M¼male.
aFISH to examine the copy number status of chromosomes 3 and 8 in UM, using centromeric
probes. Any combination in which there is a relative gain (or genetic imbalance) in copies of chromosome 8 compared with chromosome 3 is considered to be a poor prognosis
(Patel et al, 2001).
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sMedium was then removed and coverslips were rinsed once in PBS
at 371C. Cells were fixed in 3% paraformaldehyde in PBS containing
0.1% Triton X-100 for 20min at room temperature and then
extensively washed (2 15min in PBS containing 0.1% Triton X-
100 and 0.15% bovine serum albumin, 1 10min in PBS containing
0.3% Triton X-100 and 1 15min in PBS containing 0.1% Triton X-
100 and 0.15% bovine serum albumin) before incubation with rabbit
polyclonal anti-g-H2AX antibody (ser 139) (Cell Signaling Technology,
Inc., Danvers, MA, USA), at a dilution of 1:1000, for 16h at
41C. The coverslips were subsequently washed (as above) followed
by 1-h incubation at room temperature with Cy-3-conjugated goat
rabbit IgG antibody (Zymed Labs., San Francisco, CA, USA) at a
concentration of 1:500 as required, and finally washed again as
above. Coverslips were washed briefly in PBS, DNA stained with
1mgml
–1 To Pro (Molecular Probes, Paisley, UK) and finally
mounted in SlowFade Antifade (Molecular Probes). Images were
obtained with a Zeiss LSM 510 inverted confocal microscope
(Carl Zeiss Ltd., Welwyn Garden City, UK) using planapochromat
63X/NA 1.4 oil immersion objective and excitation wavelengths
488, 546 and 630nm. Through focus maximum projection images
were acquired from optical sections 0.50mm apart and with a
section thickness of 1.0mm. The frequencies of cells containing foci
were determined in at least three separate experiments. At least 50
nuclei were counted in each experiment.
Cell cycle analysis
Cells were fixed in 70% methanol and left overnight at –201C.
After washing in PBS, cells were stained with propidium iodide
(PI)/RNaseA solution (50mgml
–1PI, 100mgml
–1RNaseA) for at
least 30min. Samples were analysed by flow cytometry (Becton-
Dickenson FACSort; BD Biosciences, Oxford, UK, 488nm laser).
COMET assay
The Comet Assay reagent kit from Trevigen (Gaithersburg, MD,
USA) was used according to the manufacturer’s instructions.
Briefly, 1 10
6 cells were treated with or without 1mgml
–1 MMC
for 1h. The cells were then washed in PBS and re-suspended in
3ml PBS. Next, 2 10
5 cells were treated with or without 10Gy
ionising radiation (IR) and mixed with 250ml of Comet
LMAgarose; 75ml of the agarose mix was immediately transferred
onto a CometSlide. The slides were immersed in pre-chilled lysis
solution from the kit (approximately 5ml per slide) and incubated
at 41C for 1h before being transferred to an alkaline solution pH
413 (0.6g NaOH pellets, 200mM EDTA in 50ml ddH2O) for 1h at
room temperature in the dark. The slides were subject to
electrophoresis for 30min in alkaline electrophoresis buffer
(300mM NaOH, 1mM EDTA) at 20V (1Vcm
–1)a t41C. Following
electrophoresis, the slides were washed twice in ddH2O for 5min
then immersed in 70% ethanol for 5min. The slides were then left
to dry at room temperature in the dark for approximately 20min
before adding 50mlo f1   SYBR Safe DNA gel stain onto each
sample for 10min and leaving at room temperature in the dark
until dry. Samples were visualised using a Nikon TE200 inverted
microscope (Nikon instruments, Kingston, UK) and images
recorded using a Hamamatsu C4742-95 digital camera
(Hamamatsu photonics, Welwyn Garden City, UK). Analysis of
the average tail moment (TM) from at least 100 cells over three
separate experiments was carried out using the TriTek CometScore
Freeware v1.5 software package (TriTek Corporation, Sumerduck,
VA, USA). The MMC-induced percentage decrease in TM was then
calculated using the formula set out below to determine the
quantity of ICLs formed in each cell line (Pichierri et al, 2002).
%decreaseinTM ¼
1 
TM of IR and MMC treated sample   TM of untreated sample
TM of IR treated sample   TM of untreated sample

 100
Western blotting
Cells from established and short-term cultures were lysed in whole
cell lysis buffer (50mM HEPES, 150mM NaCl, 1mM EDTA, 1mM
EGTA, 10% glycerol, 1% Triton X100, complete protease inhibitor
complex (Roche), phosphatase inhibitor complex 1 and phosphatase
inhibitor complex 2 (Sigma, Dorset, UK). An aliquot of 50mgt o t a l
protein was run on an SDS–PAGE gel and transferred to Hybond
ECL membrane (Amersham Pharmacia, GE Healthcare Life Sciences,
Little Chalfont, UK). This membrane was immunoblotted with rabbit
anti-CYP450R (1:1000, Abcam, Cambridge, UK), goat anti-NQO1
(1:1000, Abcam) and rabbit anti-b-ACTIN (1:2000, Sigma)
antibodies, in 5% milk overnight. After addition of the appropriate
HRP-conjugated secondary antibody and further washes, immunor-
eactive protein was visualised using ECL reagents (Amersham
Pharmacia) following the manufacturer’s instructions.
RESULTS
UM is resistant to the interstrand cross-linking agent MMC
Both the established UM cell lines were resistant to MMC in the
clonogenic survival assay (at 50nM for both SOM 196b and SOM
157d compared with each of the control cell lines Po0.001 in
Student’s t-test). IC50 values of approximately 85nM were
observed compared with other cell lines whose IC50 values varied
from 5 to 15nM (Figure 1A). To confirm that this was not a cell
line-specific phenomenon, the response of 13 short-term primary
UM cultures was investigated. As a result of the slower growth rate
of short-term primary UM cultures, sensitivity was limited to using
an MTT rather than a clonogenic assay. Again compared with a
panel of other cell lines and commercially available primary
fibroblasts from healthy individuals, all the UM tested were
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Figure 1 Uveal melanoma is resistant to MMC. (A) Clonogenic survival
of UM (SOM 157d, SOM 196b) and control cell lines after 10 days in
increasing doses of MMC. Average and s.d. of at least three repeats is
shown. (B) Survival as measured by MTT assay of short-term primary UM
cells after 14 days in 50nM MMC. Cells were extracted from short-term
primary UM cultures and tested before passage 5. Survival fraction is the
OD value in MMC/the OD value seen in the same cell line grown for 14
days without treatment. Average and s.d. of three repeats are shown,
except for two primary cultures where limited passages meant that one
repeat was completed, in this case the value obtained from one repeat is
shown without error bars.
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sresistant to MMC (at 50nM for each primary culture compared
with each of the control cell lines Po0.001 in Student’s t-test
(Figure 1B).
MMC induces fewer DNA ICLs in UM than control cell
lines
In order to determine why UM is resistant to MMC, the level of
ICLs induced by MMC was investigated. Damage induced by a
relatively high dose of MMC (150mM) after just 1-h treatment was
determined. As repair of ICLs is a slow process this allowed us to
eliminate the possibility that any changes in the damage produced
were a consequence of a change in the equilibrium between
damage and repair. ICLs can be detected in single cells using a
modified form of the COMET assay (Figure 2A). The MMC-
induced decrease in migration of DNA out of the cells (TM) is
directly proportional to the amount of ICLs present in the sample.
In control cell lines (WM793, HCT116 and SW480), MMC
decreased migration of 40–50% of DNA out of cells (% decrease
in TM). In contrast, at the same dose in the UM cell lines MMC
only decreased the migration of DNA by 10% (Figures 2B and C).
This indicates that MMC does not induce the same level of ICLs in
UM as in controls and may account for the MMC resistance seen
above.
Upon DNA damage, histone H2AX is phosphorylated at Ser139
(g-H2AX), this can be visualised in cells as foci forming at sites of
damage (Rogakou et al, 1998). To further confirm that less DNA
damage is induced in these cells, the level of g-H2AX foci induced
by MMC in UM and control cells was assessed (Figure 3A). In line
with other published studies, incubation of control cells for 1h
with 90nM MMC induced a four-fold increase in g-H2AX foci
formation (P¼2.5 10
 5). However, in UM cell lines the same
dose of MMC did not induce a significant increase in foci
formation, supporting our hypothesis that resistance to MMC in
UM is because less damage is induced.
As a result of DNA damage, MMC causes cells to accumulate in
G2 phase of the cell cycle. Following 24-h treatment with 90nM
MMC, there was no difference in the percentage of cells in G2 in
treated or untreated UM cell populations (Figure 3B). This was in
contrast to WM793 where there was a 1.5-fold significant increase
(P¼0.04) in the percentage of cells in G2 following MMC
treatment.
Taken together, these results suggest that UM is resistant to
MMC because the same dose of chemotherapeutic agent does not
induce a similar degree of DNA damage.
UM cell lines and short-term primary UM cultures exhibit
reduced expression of CYP450R
The interaction of MMC with DNA can only occur following the
reductive activation of MMC by various cellular reductases (Iyer
and Szybalski, 1963), such as cytochrome P450 reductase
(CYP450R) and DT-diaphorase (DTD – also known as NQO1).
As the formation of ICLs is significantly reduced in UM cell lines,
the protein expression of these two reductases was investigated
using western blot analysis (Figure 4A). There was a decreased
expression of the reductase CYP450R in all UM cell lines compared
with WM793, HCT116 and SW480, whereas DTD expression was
normal. Interestingly, MRC5VA also showed a reduced expression
of this protein, which may account for its slightly reduced
sensitivity to MMC (Figure 1A). Consistent with this finding,
CYP450R expression was also decreased in all primary UM short-
term cultures tested (Figure 4B) but insufficient cell number
precluded the analysis of DTD expression in short-term cultures of
UM. These data support the hypothesis that resistance of UM to
MMC is due to a reduced induction of DNA damage and suggest
that this is because MMC is not processed into its active
intermediate as efficiently as in other cells.
Complementation of UM cell lines with CYP450R increases
sensitivity to MMC
To confirm the association between CYP450R expression and
MMC resistance, the bicistronic CYP450R expressing vector pEF-
P450R-IRES-P (CYP450R) (Cowen et al, 2003) or an empty vector
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Figure 2 Mitomycin C induces fewer DNA ICLs in UM. (A) Average TM in UM (SOM 157d, SOM 196b) and control cell lines untreated, treated with
10Gy IR or pretreated with 150mM MMC for 1h before being treated with IR. The average TM was calculated using CometScore software where at least 50
cells were analysed on each of three occasions and the s.d. is shown. Significance was determined using the Student’s t-test where n¼3 and Po0.01 is
indicated by **. (B) MMC-induced percentage decrease in migration calculated for each cell line. The decrease is directly proportional to the amount of ICLs
formed. Average and s.d. are shown for at least two repeats. (C) Representative COMET assay images for each of the treatments. Images were obtained
using the full spectrum function of the CometScore computer software. Cells were originally stained with SYBR Safe DNA gel stain.
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scontrol was transiently expressed in SOM 196b and WM793 cell
lines (Figure 5). A clonogenic assay for MMC sensitivity was
performed 24h after transfection. Complementing WM793 with
the CYP450R plasmid did not significantly affect the sensitivity of
these cells to MMC (Figures 5A and B). In SOM 196b, however,
complementation with CYP450R significantly increased the
sensitivity to MMC compared with non-complemented and empty
vector controls (P¼0.02 and P¼0.008, respectively) (Figures 5C
and D). It is therefore likely that the resistance to MMC in UM is
caused by defective CYP450R expression, altering the ability of
these cells to metabolise MMC. The initial findings in untrans-
fected cells are shown for reference.
UM is also resistant to cisplatin
Another commonly used cross-linking agent is cisplatin (Siddik,
2003). Unlike MMC, cisplatin does not require activation by
CYP450R, however, cross-resistance has been seen (O’Dwyer et al,
1996). The sensitivity of UM cell lines to cisplatin was therefore
tested using a clonogenic assay. The induction of cross-links is
lethal to cells because it blocks DNA replication, so cross-
resistance to a different type of replication inhibitor, HU, was
also tested. As with MMC, UM cell lines were resistant to cisplatin
(Figure 6A), however, complementation with CYP450R did not
reverse this resistance (Figure 6B). In contrast, UM did not show
resistance to HU, which does not cause cross-links but blocks
replication by inhibiting ribonucleotide reductase (Figure 6C).
Thus, although resistance in UM is specific to cross-linking agents
rather than to replication inhibitors in general, resistance to
cisplatin it is not directly due to lack of CYTP450R.
DISCUSSION
Here, we show that UM is resistant in vitro to treatment with the
interstrand cross-linking agents MMC and cisplatin but not to the
replication inhibitor HU. Mitomycin C induces DNA ICLs, such
lesions prevent DNA from unwinding and thus block replication
and transcription. If left unrepaired, ICLs can trigger apoptosis
and are lethal to cells. The induction of DNA damage in cells
therefore accounts for the use of MMC as a chemotherapeutic
agent to selectively kill actively replicating cells. Resistance to
MMC can be due to several different mechanisms. First, a
downregulation of the apoptotic response can occur in tumours
allowing cells with damaged DNA to persist. Second, an
upregulation of the ICL repair pathway can occur, allowing cells
to cope with the damage and thus survive. Finally, as MMC needs
to be activated in cells in order to damage DNA and induce death,
downregulation of the activating enzymes can result in less damage
at the same dose of drug, thus less killing. Our findings suggest
that chemo-resistance is likely to be due, at least in part, to the low
expression of the bioreductive enzyme CYP450R. This finding
contributes to our understanding of chemo-resistance in UM,
helping to explain why some treatments have been ineffective.
The CYP450R and DTD reductases have a major role in the
anticancer activity of interstrand cross-linking agents, such as
MMC and thus the expression of these enzymes and their
activation have been the subject of a number of studies
investigating chemo-resistance. For example, using CHO cells
expressing the bacterial MMC resistance-associated protein, it was
found that the resistance to MMC could be reduced significantly by
the overexpression of DTD and CYP450R (Baumann et al, 2001).
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Figure 3 Mitomycin C induces fewer g-H2AX foci and less cell cycle
arrest in UM. (A) Quantification of g-H2AX foci formation in UM (SOM
157d, SOM 196b) and control cell lines with and without incubation in
90nM MMC for 1h. Average and s.d. of three repeats is shown. Significance
was calculated using the Student’s t-test where n¼3 and Po0.001 is
indicated by ***. (B) Percentage of cells in G2-phase of the cell cycle with
or without incubation in 90nM MMC for 24h as measured by PI staining.
Average and s.d. of three repeats is shown. Significance was calculated using
the Student’s t-test where n¼3 and *Po0.05.
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Figure 4 Uveal melanoma exhibit reduced expression of CYP450R.
(A) Western blot for cytochrome p450 reductase (CYP450R), DTD
(NQO1) and b-ACTIN protein expression in UM (SOM 157d, SOM
196b) and control cell lines. (B) Western blot for CYP450R and b-ACTIN
protein expression in cells extracted from primary UM short-term cultures
and tested before passage 5.
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CYP450R was positively correlated with MMC sensitivity in these
tumours (Gan et al, 2001). Our data in UM add to evidence that
resistance to MMC and cisplatin can be the result of decreased
expression of cellular reductases.
Previous studies of UM have noted the expression of genes
associated with drug resistance, including certain apoptosis or
proliferation genes, for example, MDM2 and cyclin D2 (Coupland
et al, 1998, 2000). Although we cannot rule out the function of
these genes in MMC resistance in UM, as unrepaired ICLs can
trigger apoptosis, our finding of less ICLs in UM suggests that the
primary cause of MMC resistance is upstream of the apoptotic
response. Differential expression of well-characterised multidrug
resistance genes known to be associated with chemo-resistance
have also been reported in UM, including p-glycoprotein and
MPR1 (Chevillard et al, 1996; McNamara et al, 1996; van der Pol
et al, 1997), both of which have been associated with MMC
resistance. Here, we found that all short-term cultures and two UM
cell lines (15 UM in total) had reduced expression of CYP450R, and
given that expression of CYP450R could restore sensitivity, our
findings suggest that reduced expression of this gene specifically
contributes to resistance to the replication inhibitor MMC.
Uveal melanoma was also resistant to cisplatin. Cisplatin is not
metabolised by CYP450R and transfection with CYP450R did not
reverse resistance suggesting that an alternative mechanism is
responsible for cisplatin resistance. Fast reductive activation of
MMC by CYP450R promotes the formation of ICLs. DT-diaphorase
activation of MMC, however, is slower and leads to the formation
of the relatively non-toxic metabolite 2, 7-diaminomitosene (2,
7-DAM) (Suresh Kumar et al, 1997). DT-diaphorase expression
was not altered, but it is possible that in the absence of competition
for substrate by CYP450R the activity of DTD maybe upregulated.
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has previously been correlated to increased DTD activity although
it was not clear why increased DTD caused resistance to cisplatin
(O’Dwyer et al, 1996). If over time the reduced expression of
CYP450R leads to increased DTD activity in UM, this change in
DTD activity may not be reversed by the transient expression of
CYP450R. Thus, an alternative explanation for cisplatin resistance
seen by us and others (Schmittel et al, 2005) may be increased
activity of DTD as an indirect consequence of low CYP45R
expression.
As we found that UM cell lines were as sensitive to HU as other
cancer cell lines, it is possible that other replication inhibitors
would be more useful as chemotherapeutics for UM. There are,
however, no reports of the efficacy of HU in the treatment of UM
to validate this premise.
All UM tested for sensitivity to MMC showed resistance and
displayed reduced CYP450R expression, regardless of clinical or
genetic parameters (Table 1). As the primary UM were represen-
tative of both genetically balanced and imbalanced tumours for
chromosomes 3 and 8, as determined by fluorescent in situ
hybridisation, it is unlikely that MMC resistance arises as a
consequence of these previously identified genetic changes.
Equally, there seems to be no association with clinical phenotypes
such as cell type or tumour location. All UM tested were, however,
large enough to require treatment by enucleation, we cannot
therefore exclude the possibility that MMC resistance is specifically
the province of larger UM. Although the point at which resistance
to MMC is developed in UM is unclear, it is reasonable to assume
that as the UM tested here had no previous chemotherapy, it is
unlikely that this resistance arises in response to exposure, but is
in fact more innate. Owing to the limited cell numbers available
form short-term cultures of UM, it has not been possible to
correlate CYP450R expression levels to the level of resistance
shown. Doing so would be of value, as a minority of UM maybe
sensitive to MMC (Myatt et al, 1997). If resistance and CYP450R
levels are correlated, then screening for this gene may allow
identification of patients who would be responsive to cross-linking
therapy. Unlike UM conjunctival melanoma can be treated with
MMC suggesting depletion of CYP450R in UM is specific to UM
rather than melanomas in general.
Currently, although surgery is successful in eliminating the
primary tumour, chemotherapy is unable to prevent recurrence
and metastasis. This failure is a reflection of multiple mechanisms
for chemo-resistance that are present in UM. Here, we uncover
another such strategy for resistance. However, our data demon-
strating that the complementation of UM with CYP450R can
restore sensitivity combined with the development of gene
therapies to alter gene expression in cells, may offer hope that
by restoring the metabolising gene, tumours may be successfully
treated with cross-linking agents in the future. Indeed early studies
have shown that intratumoral injection of a vector expressing
CYP450R in an adenoviral context can sensitise previously
resistant xenografts to MMC (Cowen et al, 2003). As metastasis
is uniformly fatal, usually within a few months of diagnosis and
despite systemic therapy (Kujala et al, 2003; Bedikian, 2006), our
finding and the potential use of gene therapy to sensitise to MMC
may be of particular relevance.
In summary, we have shown here that UM cell lines and primary
tumours are resistant to MMC. Exposure to MMC did not induce
DNA ICLs in UM and expression of the bioreductive enzyme
CYP450R was reduced. Complementation of UM with CYP450R
restored sensitivity to MMC and we therefore suggest that
resistance is due to a defect in the bioactivation of MMC.
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